Lung Cancer Home > Xalkori and Breastfeeding
Although it is unknown whether Xalkori (crizotinib) passes through human breast milk, this drug has the potential to cause dangerous side effects, such as problems with the lungs, liver, and heart. Due to these potential risks, the manufacturer of the drug recommends that women avoid breastfeeding during Xalkori treatment.
Can Breastfeeding Women Take Xalkori?Xalkori® (crizotinib) is a prescription medication approved for the treatment of late-stage, non-small cell lung cancer. Non-small cell lung cancer is the most common type of lung cancer. It generally grows slower than small cell lung cancer. Xalkori is unique because it is only approved for use in people who have an abnormal gene known as the anaplastic lymphoma kinase (ALK) gene. This gene causes cancer development and growth in a small group of people.
At this time, it is unknown if this medication passes through human breast milk. The manufacturer recommends women not breastfeed while taking Xalkori. If you are nursing or planning to start, talk with your healthcare provider before taking this medication.